Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 2/20 | 0.52 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.52 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
| ▸ | TNF | P01375 | 1/20 | 0.50 |
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30844631 | 1.00 | PPARA (0.55) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL28430224 | 1.00 | PPARA (0.55) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL30416417 | 1.00 | PPARA (0.55) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL28430225 | 1.00 | PPARA (0.55) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL15381001 | 0.90 | PPARA (0.48) | PPARACTSSPPARGTNFMDM4 | |
| SCHEMBL8749905 | 0.90 | MDM4 (0.51) | MDM4TP53MDM2CASP3 | |
| SCHEMBL13878600 | 0.88 | CTSS (0.59) | PPARACTSSKLK7KLK5PPARG | |
| SCHEMBL30844644 | 0.88 | HDAC1 (0.52) | CTSSTNFMDM4TP53CASP3 | |
| SCHEMBL25444784 | 0.88 | SYK (0.53) | CTSSTNFMDM4TP53MDM2 | |
| SCHEMBL29902226 | 0.88 | SYK (0.53) | CTSSTNFMDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| US-11628160-B2 | Compositions and methods for treating brain injury | AZEVAN PHARMACEUTICALS, INC. (US) | 2023-04-18 | — | — | US | disclosed |
| EP-3122743-B1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | AZEVAN PHARMACEUTICALS INC (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | AZEVAN PHARMACEUTICALS, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | disclosed |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS INC (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-04-02 | — | — | US | disclosed |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2019-07-30 | — | — | US | disclosed |
| US-20120220765-A1 | BETA-LACTAMYL PHENYLALANINE, CYSTEINE, AND SERINE VASOPRESSIN ANTAGONISTS | KOPPEL GARY A (US) | 2012-08-30 | — | — | US | disclosed |
| US-8048874-B2 | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2011-11-01 | — | — | US | disclosed |
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-01-21 | — | — | US | disclosed |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | AZEVAN PHARMACEUTICALS, INC. | 2009-07-02 | — | — | US | disclosed |
| US-20080280870-A1 | Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists | AZEVAN PHARMACEUTICALS, INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008034032-A2 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| US-7268125-B2 | β-lactamyl vasopressin V1a antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2007-09-11 | — | — | US | disclosed |
| US-7119083-B2 | β-Lactamyl vasopressin V1a Antagonists | AZEVAN PHARMACEUTICALS, INC. (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1434763-A2 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | Serenix Pharmaceuticals, LLC (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003031407-A2 | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS | SERENIX PHARMACEUTICALS, LLC (US) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | PPARA 2116/4885CTSS 150/4885KLK7 798/4885 |
| US-20200102294-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | PPARA 478/4885CTSS 505/4885KLK7 2207/4885 |
| US-20080280870-A1 | Beta-Lactamyl Phenylalanine, Cysteine, and Serine Vasopressin Antagonists | AVPR2, AVPR1A, AVPR1B | PPARA 2356/4885CTSS 1214/4885KLK7 1308/4885 |
| US-20120220765-A1 | BETA-LACTAMYL PHENYLALANINE, CYSTEINE, AND SERINE VASOPRESSIN ANTAGONISTS | AVPR2, AVPR1A, AVPR1B | PPARA 2356/4885CTSS 1214/4885KLK7 1308/4885 |
| US-10953001-B2 | Methods for treating post traumatic stress disorder | GPX4, CRH, TXN | PPARA 2002/4885CTSS 568/4885KLK7 818/4885 |
| US-20100016274-A1 | BETA-LACTAM CANNABINOID RECEPTOR MODULATORS | CNR2, CNR1, FAAH2 | PPARA 147/4885CTSS 2582/4885KLK7 4668/4885 |
| US-20200276167-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | PPARA 2116/4885CTSS 150/4885KLK7 798/4885 |
| US-20090170825-A1 | BETA-LACTAMYLALKANOIC ACIDS FOR TREATING PREMENSTRUAL DISORDERS | GABBR1, GABBR2, ALAD | PPARA 88/4885CTSS 2586/4885KLK7 2818/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | PPARA 478/4885CTSS 505/4885KLK7 2207/4885 |
| US-20230123729-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES | HTT, AVPR2, AVPR1B | PPARA 478/4885CTSS 505/4885KLK7 2207/4885 |
| US-10364236-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | PPARA 478/4885CTSS 505/4885KLK7 2207/4885 |
| US-11628160-B2 | Compositions and methods for treating brain injury | FABP7, PYGB, CHAT | PPARA 2116/4885CTSS 150/4885KLK7 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.